Valuation: Sunho Biologics, Inc.

Market Cap 906M 1.06B 135M 118M 111M 101M 189M 12.97B 190M 1.33B 515M 6.6B 508M 497M 21.22B P/E 2023 *
-
P/E 2024 -5.67x
Enterprise Value 490M 574M 73.13M 63.77M 60.21M 54.68M 102M 7.02B 103M 721M 278M 3.57B 275M 269M 11.48B EV / Sales 2023 *
-
EV / Sales 2024 3,059x
Free-Float
32.45%
Yield 2023 *
-
Yield 2024 -
6 months-0.16%
Current year-3.77%
Current year 5.49
Extreme 5.49
8
1 year 5.49
Extreme 5.49
8.2
3 years 3
Extreme 3
15.42
5 years 3
Extreme 3
15.42
10 years 3
Extreme 3
15.42
Manager TitleAgeSince
Chief Executive Officer 44 23/01/2026
Director of Finance/CFO 47 22/07/2023
Corporate Secretary 35 22/07/2023
Director TitleAgeSince
Chairman 53 22/07/2023
Director/Board Member 44 21/07/2023
Director/Board Member 52 22/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-17.01% - 124M
+0.11%+2.71%+0.44%+26.85% 46.28B
-1.12%+1.78%+42.30%+27.55% 43.85B
-3.04%-6.29%+338.56%+515.97% 40.93B
-0.74%+1.25%+4.92%+67.98% 39.89B
-0.50%+0.67%+10.29%+41.28% 29.5B
-0.46%+4.22%+22.81%+139.44% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.19%+38.68% 15.22B
-3.14%+31.91%-11.79% - 14.05B
Average -1.04%+3.37%+45.86%+122.54% 26.25B
Weighted average by Cap. -1.10%+1.87%+68.00%+130.90%

Financials

2023 2024
Net sales 17.53M 20.53M 2.62M 2.28M 2.15M 1.96M 3.67M 251M 3.68M 25.8M 9.96M 128M 9.83M 9.61M 411M 38K 44.49K 5.67K 4.94K 4.67K 4.24K 7.94K 544K 7.98K 55.92K 21.58K 277K 21.3K 20.83K 890K
Net income -133M -155M -19.8M -17.27M -16.3M -14.8M -27.74M -1.9B -27.85M -195M -75.36M -966M -74.38M -72.73M -3.11B -79.96M -93.61M -11.93M -10.4M -9.82M -8.92M -16.71M -1.14B -16.78M -118M -45.41M -582M -44.82M -43.83M -1.87B
Net Debt -201M -235M -29.99M -26.15M -24.69M -22.42M -42.01M -2.88B -42.19M -296M -114M -1.46B -113M -110M -4.71B -416M -487M -62.09M -54.14M -51.12M -46.42M -86.97M -5.96B -87.34M -612M -236M -3.03B -233M -228M -9.75B
Logo Sunho Biologics, Inc.
Sunho Biologics Inc is a company mainly engaged in the research, development and production of biotechnology. The Company is primarily engaged in the discovery, development and commercialization of biologics that modulate the immune microenvironment by directly modulating the innate and adaptive immune systems. The Company has three core products, namely IAH0968, IAP0971 and IAE0972. IAH0968 is an antibody-dependent cell-mediated cytotoxicity-enhancing monoclonal antibody. IAP0971 and IAE0972 are both antibody cytokines.
Employees
-
  1. Stock Market
  2. Stocks
  3. 2898 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!